It is currently the only FGFR2-targeting drug with Breakthrough Designation by the FDA for frontline treatment of FGFR2b-overexpressing (defined as >10% of tumor cells staining positive for FGFR2b IHC) metastatic and locally advanced gastric and gastroesophageal adenocarcinoma [77]. Here, FGFR2 is linked to neoplasm.